Amivantamab Monotherapy for Lung Adenocarcinoma With Leptomeningeal Seeding: A Case Report

Area of Science:

• Oncology
• Medical Research

Background:

• Non-small cell lung cancer (NSCLC) often harbors driver mutations like epidermal growth factor receptor (EGFR) exon 20 insertions.
• These mutations confer resistance to standard tyrosine kinase inhibitors (TKIs), leading to poor prognosis.
• Amivantamab, a bispecific antibody targeting EGFR and MET, shows efficacy in NSCLC with EGFR exon 20 insertion mutations.

Purpose of the Study:

• To evaluate the therapeutic activity of amivantamab monotherapy in a patient with NSCLC and leptomeningeal seeding (LMS).
• To assess the clinical and radiologic response to amivantamab in a patient with central nervous system metastases after failure of first-line therapy.

Main Methods:

• Case report of a single patient with NSCLC.
• Treatment with amivantamab monotherapy.
• Clinical and radiologic assessment of response.

Main Results:

• The patient experienced leptomeningeal seeding (LMS) after first-line therapy failure.
• Amivantamab monotherapy led to a marked clinical and radiologic response.
• This suggests potential efficacy against central nervous system metastases in NSCLC.

Conclusions:

• Amivantamab monotherapy may be effective in treating NSCLC patients with leptomeningeal seeding.
• Further investigation is warranted to confirm amivantamab's role in managing CNS metastases in NSCLC.
• This case highlights a potential treatment option for a difficult-to-treat NSCLC complication.